Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
DNLI
DNLI
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
DNLI News
Relmada Therapeutics Shares Surge 40.8% on Promising Trial Data
7h ago
Benzinga
FDA Rejects Multiple Experimental Drug Applications, Raising Investor Concerns
3d ago
CNBC
FDA Drug Approval Uncertainty Intensifies
3d ago
Newsfilter
Denali Therapeutics Reports Q4 Results and Stock Offering
Feb 26 2026
seekingalpha
Shifting Trends in Biotechnology Mergers and Acquisitions
Feb 19 2026
Globenewswire
REGENXBIO Faces FDA Challenges for Gene Therapy Approval
Feb 10 2026
Newsfilter
REGENXBIO's RGX-121 BLA Accepted by FDA Under Accelerated Approval Pathway
Feb 10 2026
Benzinga
Denali Therapeutics Advances in Hunter Syndrome Treatment
Feb 05 2026
Newsfilter
Denali Therapeutics Presents Clinical Data at WORLDSymposium 2026
Jan 29 2026
Yahoo Finance
Denali Therapeutics (DNLI) Offers Covered Call with 2.60% Potential Return
Jan 20 2026
NASDAQ.COM
Denali Therapeutics Advances Tividenofusp Alfa with FDA Priority Review for Hunter Syndrome
Dec 30 2025
Globenewswire
Denali Therapeutics Advances Tividenofusp Alfa with Promising Phase 1/2 Results for Hunter Syndrome
Dec 30 2025
Newsfilter
Denali Therapeutics Prices Public Offering at $200 Million
Dec 10 2025
Newsfilter
Denali Therapeutics Prices Public Offering at $17.50 per Share, Raising $200 Million
Dec 10 2025
Globenewswire
Denali Therapeutics Reveals Pricing for Public Offering of Common Stock and Pre-Funded Warrants
Dec 10 2025
Yahoo Finance
Denali Therapeutics Plans $200 Million Stock Offering
Dec 09 2025
Globenewswire
Show More News
